UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington~~WASHINGTON, DC 20549

______________

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the

~~Pursuant to Section 13 or 15(d) of the~~ Securities Exchange Act of 1934

Date of ~~Report~~report (Date of earliest event reported): ~~May 21~~ August 19, 2015

~~Skystar~~SKYSTAR ~~Bio~~BIO-~~Pharmaceutical~~PHARMACEUTICAL ~~Company~~ COMPANY

(Exact ~~name~~Name of ~~registrant~~Registrant as ~~specified~~ Specified in Its ~~its charter~~Charter)

Nevada	001-34394	33-0901534
(State or other jurisdiction	(Commission File No.)	(IRS Employer
of incorporation)		Identification No.)

Nevada

~~4/F~~(State ~~Building~~or BOther ~~Chuangye~~Jurisdiction ~~Square,~~of ~~No. 48 Keji Road, Gaoxin District, Xi’an~~Incorporation)

Shaanxi Province, P.R. China

001-34394		33-0901534
(Commission File Number)		(IRS Employer Identification No.)

4/F Building B Chuangye Square, No. 48 Keji Road, Gaoxin District, Xi’an Shaanxi Province, P.R. China		n/a
(Address of Principal Executive Offices)		(Zip Code)

(Address of principal executive offices, including Zip Code)

(8629) 8819-3188

(Registrant’s ~~telephone~~Telephone ~~number~~Number, ~~including~~Including ~~area~~Area ~~code~~Code)

Nn/A a

(Former ~~name~~Name or ~~former~~Former ~~address~~Address, if ~~changed~~Changed ~~since~~Since ~~last~~Last ~~report~~Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing ~~obligations~~obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (~~17CFR~~17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-~~14c~~4(c))

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On ~~May~~August 2119, 2015, ~~Skystar~~ Skystar Bio-Pharmaceutical Company (the “Company”) received a notification from the Nasdaq Stock Market (“Nasdaq”) informing the Company that ~~since~~because it had not filed its Quarterly Report on Form 10-Q for the ~~fiscal~~quarter ~~year~~ ended ~~March~~June 3130, 2015, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1). The Company ~~must~~previously ~~submit~~submitted a plan of compliance ~~with~~to ~~the foregoing~~Nasdaq, ~~listing~~responded ~~deficiency~~to byan noinitial ~~later~~request ~~than~~for ~~June~~additional 15information from Nasdaq, ~~2015~~and is preparing responses to a second request for additional information from Nasdaq. If its plan is approved by the Nasdaq staff, the Company may be eligible for a listing exception of up to 180 calendar days from the date of its initial delinquent filing (its Annual Report on Form 10-K for the year ended December 31, 2014), or until October 12, 2015), to regain compliance. If the Nasdaq staff concludes that the Company will not be able to cure the deficiency, ~~or if~~ the Company ~~determines not to submit the required materials or make the required representations, the Company~~'s common stock will be subject to delisting by Nasdaq. ~~The foregoing description of the Nasdaq notification is qualified in its entirety by the text of such notification a copy of which is filed as exhibit to this filing.~~

Certain statements in this report that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995), include, among others, the Company’s expectations relating to the completion of the 2014 audit and filing of the 2014 Annual Report. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company’s control, that could cause actual results to materially differ from such statements. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertake no obligation to, update or revise any forward-looking statement.

Item 8.01 Other Events

On ~~May~~August 2225, 2015, ~~the~~ the Company issued a press release relating to the foregoing event, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits.

99.1 Press release dated August 25, 2015.

99.2 Nasdaq Notification letter dated May 21, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~Date~~Dated: ~~May~~August 2225, 2015

~~Skystar~~SKYSTAR ~~Bio~~BIO-~~Pharmaceutical~~PHARMACEUTICAL ~~Company~~COMPANY By: /s/ Bing Mei Name: Bing Mei, Title: Chief Financial Officer

Filing Compare · SKYSTAR BIO-PHARMACEUTICAL CO